Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer
Aims: This retrospective study aims to identify a possible predictive role of KRAS mutations in non-small-cell lung cancer in response to first-line pembrolizumab, either as monotherapy or combined with chemotherapy. Methods: Patients received pembrolizumab alone (n = 213) or associated with chemotherapy (n = 81). Results: A mutation in the KRAS gene was detected in 27% of patients. In patients on pembrolizumab alone, median progression-free survival in KRAS-mutated cases was longer than in wild-type cases (11.3 vs 4.4 months; p = 0.019), whereas median overall survival did not reach statistical significance (22.1 vs 12.5 months; p = 0.119). Patients receiving chemo-immunotherapy with KRAS-positive tumors had a similar progression-free survival (9.7 vs 7.3 months; p = 0.435); overall survival data were immature. Conclusion: This study suggests a correlation between KRAS status and response to pembrolizumab.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 20(2024), 7 vom: 14. März, Seite 373-380 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rossi, Sabrina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2023-0952 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369352017 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369352017 | ||
| 003 | DE-627 | ||
| 005 | 20240315233522.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2023-0952 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369352017 | ||
| 035 | |a (NLM)38445372 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rossi, Sabrina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aims: This retrospective study aims to identify a possible predictive role of KRAS mutations in non-small-cell lung cancer in response to first-line pembrolizumab, either as monotherapy or combined with chemotherapy. Methods: Patients received pembrolizumab alone (n = 213) or associated with chemotherapy (n = 81). Results: A mutation in the KRAS gene was detected in 27% of patients. In patients on pembrolizumab alone, median progression-free survival in KRAS-mutated cases was longer than in wild-type cases (11.3 vs 4.4 months; p = 0.019), whereas median overall survival did not reach statistical significance (22.1 vs 12.5 months; p = 0.119). Patients receiving chemo-immunotherapy with KRAS-positive tumors had a similar progression-free survival (9.7 vs 7.3 months; p = 0.435); overall survival data were immature. Conclusion: This study suggests a correlation between KRAS status and response to pembrolizumab | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a KRAS | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a combination therapy | |
| 650 | 4 | |a pembrolizumab | |
| 650 | 4 | |a predictive factors | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a KRAS protein, human |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Pagliaro, Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Finocchiaro, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Marinello, Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Giordano, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Bria, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Stefani, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Vitale, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Toschi, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a D'Argento, Ettore |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Armando |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 20(2024), 7 vom: 14. März, Seite 373-380 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:7 |g day:14 |g month:03 |g pages:373-380 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2023-0952 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 7 |b 14 |c 03 |h 373-380 | ||